The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes Adon30 you did allude to this in August when you said
'Completely understand about the pressures they are facing down hole and the need to be even more cautious'
The Company has arranged an equity capital raising, with existing sophisticated and institutional investors, and clients of Novum Securities Limited, of £775,000 before expenses, through the issue of 704,545,454 new fully paid ordinary shares (Placement Shares) at GBP 0.11 pence per share (Placement). The Placement will be completed in two tranches by 7 August 2023.
The Placement is being conducted by Novum Securities Limited (Novum) as lead broker to the capital raising. Accordingly, in connection with the Placing, the Company has also agreed to issue 13,636,363 unquoted options to Novum, exercisable at GBP 0.11 pence on or before 31 July 2026 (Fee Options).
It does say among the bulletpoints:
'The Company continues to make good progress on its partnership process for Anchois, with the fundraise providing an improved financial position ahead of finalising negotiations'
YES. HERE IT IS:
Chariot (AIM: CHAR), the Africa focused transitional energy company, is pleased to announce its intention to undertake a fundraising of approximately US$18 million (£14 million) before expenses by way of a placing (the "Placing") and a direct subscription (the "Subscription") of approximately US$15 million (£11.7 million) in aggregate, and an open offer (the "Open Offer") of up to US$3 million (£2.3 million) (the Placing, Subscription and Open Offer together the "Fundraising"). Pursuant to the Fundraising, it is estimated that the Company will issue approximately 83,705,358 new Ordinary Shares pursuant to the Placing and the Subscription and up to 16,615,421 new Ordinary Shares pursuant to the Open Offer, in each case at an issue price of 14 pence per share (the "Issue Price").
Jamrock: have you done any charting for MHC following the recent consolidation?
No Zag:
has been unsuccessful.
Synergia Energy Ltd (the "Company") has today been advised by the North Sea Transition Authority ("NSTA") that one of the two licence applications made by the Company under the 1st carbon storage licencing round has been unsuccessful.
The second licence application remains under consideration by the NSTA.
Roger65: That was at 12:57:33
Interesting procedure
https://www.youtube.com/watch?v=eXnSyQ0ok04
Https://simplywall.st/stocks/gb/healthcare/aim-mhc/myhealthchecked-shares/news/myhealthchecked-lonmhc-could-become-a-multi-bagger
Let's hope so.
You're welcome jamrock, and I really hope things work out for you and all those invested in MHC.
Well to be honest: you did advise those invested here to load up at 1.00 Jamrock.
Sound advice MassiveRay: although 'Learn to take profit' is the most critical to an successful investment strategy along with 'don't be too greedy;
nissangtr786
‘Still don’t get how it is so low as there has been significantly more buys than sells since it was 29p according to LSE so in effect it should be 30p at least now’
Aim reports what is bought and sold by the strike price, and gets it wrong regularly.
https://www.londonstockexchange.com/news-article/GDR/5-million-equity-prepayment-facility/15901087
Renndava 'When they drilled 16-2 they weren’t expecting the gas'
On the contrary, they knew about the gas: this is from the rns Feb 2021
'A potential side track lateral on the State 16-2 well (the "State 16-2LN-CC") is forecast to have strong economics as a standalone investment. Utilising production profiles generated from Gaffney Cline's CPR, and updated with a $55 per BO and $60 per BO prices, the Board estimates the lateral side track could generate the following on a 2C basis:
Initial gross oil production rate: 780 barrels of oil per day
Estimated Ultimate Recovery: 550,000 BO and 1.8 billion cubic feet of gas
Return on Invested Capital: 232% at $55/BO; 314% at $60/BO
Single well net NPV-10: $5.7 million at $55/BO; $6.7 million at $60/BO'
That's a great find Cuvio. Hopefully it will serve to attract potential customers. I just feel it takes so much navigational effort to just find our products. Also, I've been looking out for Trustpilot reviews of the DNA on MHC's website, but other than the first one I noticed, there has not been a second one.
It seems we are managing to sell a few of our DNA tests on Amazon, albeit not that many. Still, let's see how things progress.
https://www.amazon.co.uk/s?k=dna+test+myhealthchecked&crid=VESTTKJP57C&sprefix=dna+test+myhealthchecked%2Caps%2C72&ref=nb_sb_noss
The subdued response of the share price despite the fine trading update and related news is a concern. I have serious doubts about the Amazon arrangement, although I would be happy to be proven wrong. With regards to Amazon, the problem is that there is a such a surfeit of related health test materials. It is going to be quite a challenge to attract the attention of customers. The Boots and Lloyds linkup provided MHC with a much more enhanced profile, which boosted sales. My view is the management should focus its energies on trying to persuade these retailers to offer the DNA testing products; perhaps this is something MHC is currently pursuing?
The issue is we have only had one Trustpilot review relating to the new DNA test. If they were flying off the shelves, you would expect to have had many more reviews, but that hasn't happened.